Arvinas (ARVN) Research & Development (2017 - 2026)
Arvinas (ARVN) recorded quarterly Research & Development of $60.3 million in Q1 2026, down 1.31% quarter-over-quarter from $61.1 million in Q4 2025, and down 33.59% on a YoY basis from $90.8 million in Q1 2025.
Arvinas (ARVN) Research & Development (2017 - 2026) Analysis & Trends
Arvinas' Research & Development history runs 10 years deep, the most recent figure standing at $60.3 million for Q1 2026.
- In Q1 2026, Research & Development fell 33.59% year-over-year to $60.3 million; the TTM figure through Mar 2026 stood at $254.7 million (down 28.19% YoY), while the FY2025 annual figure was $285.2 million, down 18.09% from the prior year.
- Research & Development was $60.3 million for Q1 2026 at Arvinas, down from $61.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $103.4 million in Q2 2023 to a low of $60.3 million in Q1 2026.
- Historically, Research & Development has averaged $81.7 million across 5 years, with a median of $84.3 million in 2024.
- The sharpest annual moves came in 2022 and 2026: Research & Development surged 90.89% in 2022, then plunged 33.59% in 2026.
- A 5-year view of Research & Development shows it stood at $98.3 million in 2022, then fell by 3.15% to $95.2 million in 2023, then decreased by 12.5% to $83.3 million in 2024, then decreased by 26.65% to $61.1 million in 2025, then retreated by 1.31% to $60.3 million in 2026.
- The last three Research & Development figures came in at $60.3 million (Q1 2026), $61.1 million (Q4 2025), and $64.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | 60.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.30 Mn |
| Dec 31, 2025 | 61.10 Mn |
| Sep 30, 2025 | 64.70 Mn |
| Jun 30, 2025 | 68.60 Mn |
| Mar 31, 2025 | 90.80 Mn |
| Dec 31, 2024 | 83.30 Mn |
| Sep 30, 2024 | 86.90 Mn |
| Jun 30, 2024 | 93.70 Mn |
| Mar 31, 2024 | 84.30 Mn |
| Dec 31, 2023 | 95.20 Mn |
| Sep 30, 2023 | 85.90 Mn |
| Jun 30, 2023 | 103.40 Mn |
| Mar 31, 2023 | 95.30 Mn |
| Dec 31, 2022 | 98.30 Mn |
| Sep 30, 2022 | 77.50 Mn |
| Jun 30, 2022 | 75.30 Mn |
| Mar 31, 2022 | 64.00 Mn |
| Dec 31, 2021 | 61.90 Mn |
| Sep 30, 2021 | 40.60 Mn |
| Jun 30, 2021 | 43.00 Mn |